Non-exclusive drug discount agreement for Infliximab subcutaneous injection (ATC L04AB02)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab zur subkutanen Injektion (ATC-Code nach WHO: L04AB02)
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
40 / 100
Risk factors
No guaranteed purchase quantities; revenue depends on prescription behavior of doctors and dispensing by pharmacies.
Buyer may terminate open-house procedure early if exclusive discount agreements are signed, which historically occurs 8...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Non-exclusive discount agreements for Infliximab subcutaneous injection (ATC L04AB02)
- Open-house model: any eligible pharmaceutical entrepreneur can participate without exclusivity
Show full summary
This is a non-exclusive drug discount agreement under §130a(8) SGB V for the active substance Infliximab for subcutaneous injection (ATC L04AB02). The agreement is offered through an open-house model, allowing any eligible pharmaceutical entrepreneur to conclude a discount agreement with AOK PLUS for insured patients in Saxony and Thuringia. The contract runs until 31 December 2026, with no guaranteed purchase volumes and a possibility of early termination if exclusive agreements are signed. The procedure is voluntarily published and not a formal public procurement under EU directives.
Risks
No guaranteed purchase quantities; revenue depends on prescription behavior of doctors and dispensing by pharmacies.
Buyer may terminate open-house procedure early if exclusive discount agreements are signed, which historically occurs 8...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with a registered office in Germany, EU, or EEA
Eligibility
- Submission of self-declaration on absence of exclusion grounds per §§123,124 GWB
Administrative
- Submission of self-declaration on EU Russia sanctions (Regulation (EU) 2022/576)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Infliximab subcutaneous injection (ATC L04AB02)
Conclusion of non-exclusive discount agreements for the supply of Infliximab subcutaneous injection to AOK PLUS. The open-house model allows any eligible pharmaceutical company to participate. No minimum volumes are guaranteed, and the agreement ends 31 December 2026. Submission is possible on a rolling basis starting from 3 December 2024.
Location
Duration
Category
Award Criteria
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab zur subkutanen Injektion (ATC-Code nach WHO: L04AB02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 10 Nov 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 684145-2024
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
40 / 100
Risk factors
No guaranteed purchase quantities; revenue depends on prescription behavior of doctors and dispensing by pharmacies.
Buyer may terminate open-house procedure early if exclusive discount agreements are signed, which historically occurs 8...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications